Mel Hayes
Corporate Officer/Principal chez FULCRUM THERAPEUTICS, INC.
Fortune : 52 422 $ au 31/05/2024
Profil
Mel Hayes is currently the Executive Vice President-Patient Experience at Fulcrum Therapeutics, Inc. Prior to this, he held positions at Genzyme Corp., Bioverativ, Inc., Shire, Inc., Sanofi Ventures, and Baxalta, Inc. His former roles include VP-Rare Blood Disorders & Global Head-Commercial, Vice President-Hemophilia, and Global VP & Head-Global Marketing.
Mr. Hayes completed his undergraduate degree at Southern Methodist University and holds an MBA from Columbia Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 6 678 ( 0,01% ) | 52 422 $ | 31/05/2024 |
Postes actifs de Mel Hayes
| Sociétés | Poste | Début |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Corporate Officer/Principal | 02/10/2023 |
Anciens postes connus de Mel Hayes
| Sociétés | Poste | Fin |
|---|---|---|
| BAXALTA INC | Corporate Officer/Principal | - |
Shire, Inc.
 Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The company is based in Lexington, KY. | Sales & Marketing | - |
Sanofi Ventures
 Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Corporate Officer/Principal | - |
| BIOVERATIV INC | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Mel Hayes
| Southern Methodist University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
Shire, Inc.
Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The company is based in Lexington, KY. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
